×
AllNewsImagesMaps Videos Shopping Books
Search tools

Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial

Insider Monkey
Bristol-Myers Squibb Company (NYSE:BMY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds.
3 hours ago

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY)

MarketBeat
MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lessened its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 66.0% in the 1st...
2 hours ago

Chris Shibutani, MD

Bristol Myers Squibb
Learn more about Chris Shibutani, executive vice president, chief strategy officer, who leads the development and advancement of the...
6 days ago

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal

BioPharma Dive
The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that...
3 days ago

BioNTech and Bristol Myers Squibb Partner to Develop Bispecific Antibody Targeting PD-L1 and VEGF-A for Tumor Treatment

GeneOnline
BioNTech and Bristol Myers Squibb (BMS) have announced a collaboration to co-design and co-commercialize a new bispecific antibody candidate...
12 hours ago

BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem

BioSpace
Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead collaborate on an...
3 days ago

BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal

Fierce Biotech
Bristol Myers Squibb, via its RayzeBio unit, is handing $350 million in upfront cash for a phase 1-stage radiopharmaceutical therapy and...
4 days ago

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus r

GlobeNewswire
Philochem Licensing of OncoACP3 to RayzeBio for potential value of up to $1.35bn plus royalties...
4 days ago

Bristol Myers Squibb names Shibutani as EVP, chief strategy officer

ROI-NJ
Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately.
1 day ago

Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu

Yahoo Finance
In June 2025, Bristol-Myers Squibb (NYSE:BMY) announced positive results from the Phase 3 POETYK PsA-1 trial of Sotyktu, showcasing its...
3 days ago